GenoFocus Statistics
Total Valuation
GenoFocus has a market cap or net worth of KRW 107.32 billion. The enterprise value is 146.68 billion.
Market Cap | 107.32B |
Enterprise Value | 146.68B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
GenoFocus has 24.01 million shares outstanding. The number of shares has increased by 1.66% in one year.
Current Share Class | n/a |
Shares Outstanding | 24.01M |
Shares Change (YoY) | +1.66% |
Shares Change (QoQ) | +0.30% |
Owned by Insiders (%) | 32.95% |
Owned by Institutions (%) | n/a |
Float | 16.10M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.17 |
PB Ratio | 4.51 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -51.37 |
EV / Sales | 4.56 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -69.70 |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 1.39.
Current Ratio | 0.63 |
Quick Ratio | 0.45 |
Debt / Equity | 1.39 |
Debt / EBITDA | n/a |
Debt / FCF | -19.51 |
Interest Coverage | -0.93 |
Financial Efficiency
Return on equity (ROE) is -1.56% and return on invested capital (ROIC) is -3.43%.
Return on Equity (ROE) | -1.56% |
Return on Assets (ROA) | -3.05% |
Return on Capital (ROIC) | -3.43% |
Revenue Per Employee | 473.49M |
Profits Per Employee | -41.99M |
Employee Count | 68 |
Asset Turnover | 0.33 |
Inventory Turnover | 3.10 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.05% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +18.05% |
50-Day Moving Average | 3,534.40 |
200-Day Moving Average | 3,737.08 |
Relative Strength Index (RSI) | 55.07 |
Average Volume (20 Days) | 1,320,502 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GenoFocus had revenue of KRW 32.20 billion and -2.86 billion in losses. Loss per share was -125.15.
Revenue | 32.20B |
Gross Profit | 11.34B |
Operating Income | -4.77B |
Pretax Income | 276.16M |
Net Income | -2.86B |
EBITDA | -198.80M |
EBIT | -4.77B |
Loss Per Share | -125.15 |
Balance Sheet
The company has 8.46 billion in cash and 41.07 billion in debt, giving a net cash position of -32.61 billion or -1,358.09 per share.
Cash & Cash Equivalents | 8.46B |
Total Debt | 41.07B |
Net Cash | -32.61B |
Net Cash Per Share | -1,358.09 |
Equity (Book Value) | 29.51B |
Book Value Per Share | 992.09 |
Working Capital | -13.06B |
Cash Flow
In the last 12 months, operating cash flow was -1.13 billion and capital expenditures -971.49 million, giving a free cash flow of -2.10 billion.
Operating Cash Flow | -1.13B |
Capital Expenditures | -971.49M |
Free Cash Flow | -2.10B |
FCF Per Share | -87.66 |
Margins
Gross margin is 35.21%, with operating and profit margins of -14.81% and -8.87%.
Gross Margin | 35.21% |
Operating Margin | -14.81% |
Pretax Margin | 0.86% |
Profit Margin | -8.87% |
EBITDA Margin | -0.62% |
EBIT Margin | -14.81% |
FCF Margin | -6.54% |
Dividends & Yields
GenoFocus does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.66% |
Shareholder Yield | -1.66% |
Earnings Yield | -2.80% |
FCF Yield | -1.96% |
Stock Splits
The last stock split was on March 19, 2018. It was a forward split with a ratio of 2.
Last Split Date | Mar 19, 2018 |
Split Type | Forward |
Split Ratio | 2 |
Scores
GenoFocus has an Altman Z-Score of 0.37. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.37 |
Piotroski F-Score | n/a |